Tanvi Patel (@catalystinvstor) header
Tanvi Patel (@catalystinvstor) profile picture

Individual investor, main focus biotech. Tweets are ideas not recommendations.

Joined April 2013
Photo by Tanvi Patel (@catalystinvstor)Photo by Tanvi Patel (@catalystinvstor)Photo by Tanvi Patel (@catalystinvstor)Photo by Tanvi Patel (@catalystinvstor)Photo by Tanvi Patel (@catalystinvstor)Photo by Tanvi Patel (@catalystinvstor)Photo by Tanvi Patel (@catalystinvstor)Photo by Tanvi Patel (@catalystinvstor)Photo by Tanvi Patel (@catalystinvstor)Photo by Tanvi Patel (@catalystinvstor)
Tanvi Patel retweeted
$MNKD Cantor Fitzgerald maintains MannKind at Overweight, raises price target to $10 from $8 Making great progress. $XBI
1
4
258
If Moderna (or partner) gains approval for mRNA cancer vaccine (such as its individual neoantigen therapy, mRNA-4157 / V940) that relies on $ABUS Arbutus/Genevant’s patented LNP delivery IP, $MRNA would need to negotiate a separate commercial license with Genevant/Arbutus for it.
1
4
692
$MNKD ‘s newest FDA approved Furoscix ReadyFlow is an at-home treatment option designed to help adults with heart failure or chronic kidney disease address fluid overload earlier, before worsening symptoms may lead to emergency department visits, hospitalization, or readmission
1
124
Between rapid drug-delivery innovations and an expanding pipeline, $MNKD is set for growth in revenue and earnings. The gap between underlying fundamentals and market valuation is getting harder to ignore. Great takeaway 👇 by @Michaelluh on Stocktwits
1
120
$MNKD Wells Fargo raised PT to $14 from $11 on higher Furoscix & ‘201 probability of success, while keeping an Overweight rating on the shares. Informed by competitor PK/tissue exposure data, firm’s best estimate is that ‘201 is likely achieving better tissue exposure vs Ofev
1
106
Tanvi Patel retweeted
MannKind is excited to announce that the U.S. Food and Drug Administration (FDA) has approved a new, transformative delivery option for the treatment of fluid buildup due to heart failure or chronic kidney disease. Designed for ease of use, this at-home administration option is delivered subcutaneously in seconds. Learn more in the Company Announcement here: bit.ly/4wgsmJ7 ISI: bit.ly/4wgsmJ7 Prescribing info: bit.ly/45gCm9r
3
1
10
821
Tanvi Patel retweeted
$LCID has delivered a cease-and-desist letter to @EV_carba regarding reporting that falsely claimed the company was considering bankruptcy or a take-private transaction. Those claims have been publicly and unequivocally denied, including in an SEC filing.
89
91
31
563
118,519
Great news for kids. U.S. Food and Drug Administration (FDA) has approved Afrezza® (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes #Needlefreeinsulin #Diabetes #T1D #Type1Diabetes #T2D #WeAreNotWaiting
77
MannKind is excited to announce that the U.S. Food and Drug Administration (FDA) has approved the first needle-free treatment option for pediatric patients living with type 1 diabetes. Learn more in the Company Announcement here: bit.ly/4tYQgqV Important Safety Information: bit.ly/4tYQgqV Prescribing Information: bit.ly/4dBCEwL #Press #FDA #Diabetes #T1D
2
4
337
Eli Lilly's $LLY dealmaking spree just keeps going, but this time, company is returning to a category it's been absent from for years: vaccines & infectious diseases. $ABUS fits in this category well & they have positioned the company for sale. Hepatitis B & mRNA delivery technol
1
4
1,595
Bodes well for $ABUS as it owns (w/h Genevant) the delivery technology used for mRNA vaccines. If $LLY buy abus, would $PFE make a counter offer as they have to pay for Abus’s intellectual property PFE used for COVID vaccines anyway cnbc.com/2026/05/27/eli-lill… cnbc.com/2026/05/27/eli-lill…
4
751
$MNKD finally reclaiming what was lost! 🚀 Wrongly punished and manipulated down 55% on $UTHR Q2 misinformation—today's Q3 call set the record straight. Up 40%, but just getting started.
1
1
1
3
310
Correction, misinformation happened after UTHR Q4 earnings call and $UTHR Q1 2026 conference call (May 6, 2026) was a total narrative shift from the "stealth competition" fears of February. It served as a massive "correction" to the misinformation that previously tanked $MNKD.
129
Tanvi Patel retweeted
Tutes are buying $MNKD dip ahead of PDUFA ...
1
1
3
1,545
Tanvi Patel retweeted
𝐁𝐚𝐫𝐜𝐥𝐚𝐲𝐬 𝐌𝐢𝐚𝐦𝐢: In addition to being CEO of @MannKindCorp, Michael Castagna is a diabetic who uses his company's own product (Afrezza inhaled insulin). He demonstrated how it works. $MNKD
4
14
1
39
4,721
This confirms what some of us already knew that $Abus was the real inventor of this technology and Moderna $MRNA obtained it through back door, used it and lied about using someone else’s invention as their own for so long.
Arbutus secured legal leverage: $ABUS patents and LNP delivery platform are validated. Judgment of Infringement: Moderna $MRNA has consented to a court judgment of infringement and no invalidity for the four key patents at the center of the case.
4
905
Arbutus secured legal leverage: $ABUS patents and LNP delivery platform are validated. Judgment of Infringement: Moderna $MRNA has consented to a court judgment of infringement and no invalidity for the four key patents at the center of the case.
1
1
1,220
$MNKD earnings tomorrow $UTHR announcement
1
2
1
4
1,870